Maternal and neonatal morbidity of HELLP syndrome: 100 Cases;Morbidité maternelle et néonatale du HELLP syndrome: À propos de 100 cas à Port-Royal

Revue Sage - Femme

Volumn 3, Issue 1, 2004, Pages 9-16

  Hughes, C ^a  

^a Centre hospitalier de Lagny Marne la Vallee   (France)

Author keywords

HELLP syndrome; Morbidity; Mortality

Indexed keywords

EID: 61449248345     PISSN: 16374088     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1637-4088(04)72171-9     Document Type: Review

References (16)

1. Robert S. Egerman, MD, Baha M, Sibai, MD. HELLP Syndrome. Clinical Obstetrics & Gynecology 1999; 42: 381-9.
2. Sibai BM, Ramadan MK, Usta I et al. Maternal morbidity an mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol Octobre 1993; 169: 1000-6.
3. Magann EF, Martin JN. Twelve Steps to Optimal Management of HELLP Syndrome. Clinical Obstetrics and Gynecology Septembre 1999; 42: 532-49.
4. Magnin G, Vequeau-Goua V, Pourrat O, Pierre F et al. La préeclampsie sévère précoce : comment gérer le conflit d'intérêt foeto-maternel. J Gynecol Obstet Biol Reprod 2000. Séance plénière du 25 mai 2000; 29: 230-3.
5. Reck T, Bussenius-Karmmer M, Ott R et al. Surgical treatment of HELLP syndrome-associated liver rupture an update. European Journal of Obstetrics & Gynecology and Reproducive Biology 99 2001: 57-65.
6. Tsatsaris V, Audibert F. Le HELLP syndrome. Mises à jour en Gynécologie et Obstétrique. Ed. Vigot, Paris 1999 ; 1-21.
7. Sibaï BM, Ramadan MK, Chari RS et al. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): Subsequent pregancy outcome and long-term prognosis. Am J Obstet gynecol Janvier1995; 172: 125-9.
8. Ben Letaifa D, Hamada SB, Salem N et al. Morbidité et mortalité materno-foetale associées au HELLP syndrome. Ann Fr Anesth Réanim 2000; 19: 712-8.
9. Barton John R, Sibai Baha M. Care of the pregnancy complicated by HELLP Syndrome. Obstetrics and Gynecology Clinics of North America Juin 1991; 18: 165-78.
10. Magann EF, Graves GR, Roberts WE et al. Corticosteroids for the Enhancement of Fetal Lung Maturity Impact on the Gravida with Preeclampsia and the HELLP syndrome. Aust And NZ Journal of Obstetrics and Gynaecology 1993; 33: 127-31.
11. Magann EF, Martin RW, Isaacs JD et al. Corticosteroids for Enhanced Fetal Lung Maturation in Patients with HELLP Syndrome: Impact on Neonates. Aust NZ J Obstet Gynaecol 1993; 33: 131-5.
12. Visser W, Van Pampus MG, Treffers PE et al. Perinatal results of hemodynamic and conservative temporizing treatment in severe pre-eclampsia. European Journal of Obstetrics & Gynecology and Reproductive Biology 1994; 53: 175-81.
13. Audibert F, Coffineau A, Edouard D et al. Prise en charge du HELLP syndrome avant 32 semaines d'aménorrhée. La presse Médical 17 février 1996 ; 25 : 235-9.
14. Martin JN, Perry KG, Miles JF et al. The interrelationship of eclampsia, HELLP syndrome, and prematurity: cofactors for significant maternal and perinatal risk. British Journal of Obstetrics & Gynaecology Décembre 1993; 100: 1095-100.
15. Haddad B, Barton JR, Livingston JC et al. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: onset at ≤ 28.0 weeks' gestation. Am J Obstet Gynecol Decembre 2000; 183: 1475-9.
16. Abramovici D, Friedman SA, Mercer BM et al. Neonatal outcome in severe preeclampsia t 24 to 36 weeks' gestation: Does the HELLP (hemolysis, elevated lier enzymes, and low platelet count) syndrome matter? Am J Obstet Gynecol Janvier 1999; 180 part 1: 221-5.